Chromium carnosinate is a chelated form of chromium, a trace mineral that has been investigated for its role in glucose metabolism and insulin sensitivity. The rationale for using chromium compounds, including chromium carnosinate, in metabolic syndrome stems from evidence that chromium supplementation may improve glycemic control and lipid profiles, both of which are relevant to metabolic syndrome. However, most research has focused on other chromium forms, such as chromium picolinate, rather than chromium carnosinate specifically.

A few small clinical studies and animal models have suggested that chromium supplementation can lead to modest improvements in fasting blood glucose, insulin resistance, and lipid parameters. However, the overall quality of evidence is low to moderate, with inconsistent results across trials. For chromium carnosinate specifically, published human trials are extremely limited, and most data are extrapolated from studies on other chromium salts. Theoretical advantages of the carnosinate form (e.g., better absorption, antioxidant properties) have not been robustly confirmed in human studies.

In summary, while there is some scientific rationale and limited evidence for chromium supplementation in metabolic syndrome, the specific use of chromium carnosinate is not strongly supported by direct, high-quality clinical evidence. The evidence rating is therefore moderate to low.